Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Sales 2024 * | 19.66B 2.81B | Sales 2025 * | 23.53B 3.37B | Capitalization | 130B 18.66B |
---|---|---|---|---|---|
Net income 2024 * | 5.11B 731M | Net income 2025 * | 6.81B 974M | EV / Sales 2024 * | 5.25 x |
Net cash position 2024 * | 27.32B 3.91B | Net cash position 2025 * | 34.49B 4.93B | EV / Sales 2025 * | 4.08 x |
P/E ratio 2024 * |
25.5
x | P/E ratio 2025 * |
19.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Anders Pedersen
BRD | Director/Board Member | 73 | 03-10-31 |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B | |
-18.85% | 9.12B |